Seikagaku Launches JOYCLU Joint Function Agent in Japan

Seikagaku and partner Ono Pharmaceutical commenced launch of JOYCLU® 30mg Intra-articular Injection, a joint function improvement agent, for which Seikagaku
received manufacturing and marketing approval in Japan in 1Q21.

JOYCLU combines hyaluronic acid and an anti-inflammatory drug, chemically bound using Seikagaku’s proprietary...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us